Randomized, OpenLabel, Phase 3 Trial of Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Early Stage NSCLC
Randomized, OpenLabel, Phase 3 Trial of Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Early Stage NSCLC
The purpose of this neoadjuvant study is to compare nivolumab plus chemotherapy and chemotherapy alone in terms of safety and effectiveness, and to describe nivolumab plus ipilimumab's safety and effectiveness in treating resectable NSCLC.
This study has multiple primary endpoints.
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria apply
Capital Federal, Buenos Aires 1426, Argentina
Ciudad Autonoma de Buenos Aire, Buenos Aires 1181, Argentina
Pierre Benite Cedax, 69495, France
Kashiwa-shi, Chiba 2778577, Japan
Kitakyushu-shi, Fukuoka 8078555, Japan
Sakai-shi, Osaka 5918555, Japan
Sunto-gun, Shizuoka 4118777, Japan
Bunkyo-ku, Tokyo 1138431, Japan
Shinjuku-ku, Tokyo 1600023, Japan
Romania, 400015, Romania
Majadahonda - Madrid, 28222, Spain